ARBUTUS BIOPHARMA
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). They believe that Arbutus' comprehensive HBV pipeline of drugs and drug candidates optimally positions us to transform the HBV treatment landscape and to capitalize on the HBV global market opportunity. They are developing a portfolio ... of drug candidates with multiple mechanisms of action that They believe will result in a combination therapy to cure HBV. Specifically, They seek to effect a cure by targeting the three pillars necessary to develop a curative regimen for HBV. This includes suppressing HBV replication within liver cells, stimulating and reactivating the body’s immune system so that it can mount an effective defense against the virus and eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA, that is the source of HBV persistence.
ARBUTUS BIOPHARMA
Industry:
Biopharma Biotechnology Genetics Health Care Medical Pharmaceutical
Founded:
1992-01-01
Address:
Burnaby, British Columbia, Canada
Country:
Canada
Website Url:
http://www.arbutusbio.com
Total Employee:
51+
Status:
Active
Contact:
(604) 419-3200
Total Funding:
354.44 M USD
Technology used in webpage:
IPv6 Pound Sterling Japanese Yen Akamai Hosted Digg
Similar Organizations
BostonGene
BostonGene is a biomedical software company for advanced patient analysis and personalized therapy in the fight against cancer.
Cassava Sciences
Cassava Sciences is a clinical-stage biopharmaceutical company focused on neuroscience.
The Grunenthal Group
The Grunenthal Group is an independent, family-owned, international research-based pharmaceutical company.
Illumina
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Insmed
We are a publicly traded (NASDAQ: INSM) biopharmaceutical company dedicated to improving the lives of patients battling serious lung
Mereo Biopharma
Mereo is a new UK-based speciality biopharmaceutical company.
Mustang Bio
Mustang Bio is a clinical-stage biopharmaceutical company .
NGM Biopharmaceuticals
NGM Biopharmaceuticals is a drug discovery company developing biotherapeutics for the gastrointestinal endocrine system.
Opthea
Opthea Limited is a public Australian biotechnology company .
Progyny
Progyny is a fertility benefits management company.
Current Advisors List
Board_member
2014-01-01
Board_member
2014-12-01
Current Employees Featured
Michael Sofia Chief Scientific Officer @ Arbutus Biopharma
Chief Scientific Officer
2015-03-01
Michael J. McElhaugh Co-Founder, COO, and CBO @ Arbutus Biopharma
Co-Founder, COO, and CBO
2018-12-01
Ian C. Mortimer CFO @ Arbutus Biopharma
CFO
Bruce Cousins Executive Vice President & Chief Financial Officer @ Arbutus Biopharma
Executive Vice President & Chief Financial Officer
Karen Sims Chief Medical Officer @ Arbutus Biopharma
Chief Medical Officer
2023-07-01
David Hastings Chief Financial Officer @ Arbutus Biopharma
Chief Financial Officer
2018-06-01
Patrick Higgins Co-Founder and Chief Business Officer @ Arbutus Biopharma
Co-Founder and Chief Business Officer
William Collier Collier President and Chief Executive Officer @ Arbutus Biopharma
President and Chief Executive Officer
2019-06-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2015-01-13 | OnCore Biopharma | OnCore Biopharma acquired by Arbutus Biopharma | N/A |
| 2008-03-28 | Protiva Biotherapeutics | Protiva Biotherapeutics acquired by Arbutus Biopharma | 22.8 M USD |
Investors List
Roivant Sciences
Roivant Sciences investment in Post-IPO Equity - Arbutus Biopharma
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Arbutus Biopharma
National Institutes of Health
National Institutes of Health investment in Grant - Arbutus Biopharma
BDC Venture Capital
BDC Venture Capital investment in Venture Round - Arbutus Biopharma
Key Employee Changes
| Date | New article |
|---|---|
| 2023-11-07 | Arbutus Announces CEO, William Collier, to Retire December 31, 2023 |
| 2023-07-11 | Arbutus Biopharma appoints Karen Sims as chief medical officer |
Official Site Inspections
http://www.arbutusbio.com Semrush global rank: 7.37 M Semrush visits lastest month: 803
- Host name: 226.108.198.104.bc.googleusercontent.com
- IP address: 104.198.108.226
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Arbutus Biopharma"
Leadership Team - Arbutus Biopharma
Most recently, Tuan was CFO at Kinevant Sciences where he led finance and operation functions and implemented structure and processes within the organization to fuel growth opportunities. …See details»
About Arbutus - Arbutus Biopharma : Arbutus Biopharma
About Arbutus Specialized in virology. Focused on growth. We are a clinical-stage biopharmaceutical company with deep virology expertise and an unwavering focus on curing …See details»
Investor Relations | Arbutus Biopharma Corporation
Arbutus Biopharma Corporation (NASDAQ:ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with …See details»
Arbutus Biopharma Corporation | LinkedIn
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with …See details»
Arbutus Biopharma - Crunchbase Company Profile & Funding
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic …See details»
Arbutus Announces Changes to Board of Directors and …
Feb 25, 2025 The company is currently developing imdusiran (AB-729) for the treatment of chronic hepatitis B (cHBV). Through its ownership stake in and license agreement with …See details»
Arbutus Biopharma Corporation - Dun & Bradstreet
Company Description: Tekmira Pharmaceuticals is giving diseases the silent treatment. The biopharmaceutical company is attempting to develop therapies that inhibit or "silence" certain …See details»
Arbutus Biopharma (LON:0SGC) Company Profile & Description
Jan 31, 2025 Company profile for Arbutus Biopharma Corporation (LON:0SGC) with a description, list of executives, contact details and other key facts.See details»
Arbutus Biopharma - Craft
Oct 29, 2024 Arbutus Biopharma has 5 employees at their 1 location and $18.14 m in annual revenue in FY 2023. See insights on Arbutus Biopharma including office locations, …See details»
Arbutus Provides 2025 Corporate and Financial Update
Jan 13, 2025 Imdusiran has achieved meaningful functional cure rates in patients with cHBV when administered as combination therapy. In the first half of 2025, Arbutus is planning to …See details»
Arbutus Biopharma - Overview, News & Similar companies
May 29, 2024 Arbutus Biopharma contact info: Phone number: (267) 469-0914 Website: www.arbutusbio.com What does Arbutus Biopharma do? Founded in 1992, Arbutus …See details»
Arbutus Biopharma Corp. (Arbutus Biopharma Corp.) - 药物管线_ …
The recent global COVID-19 pandemic has highlighted treatments for coronavirus infection as an unmet medical need. The main protease (M pro) has been an important target for the …See details»
Board of Directors - Arbutus Biopharma
Board Of Directors Meet our Board.. Our board of directors is made up of healthcare leaders, innovative scientists, and more. They possess deep expertise in biopharmaceuticals, …See details»
Scientific Advisory Board - Arbutus Biopharma
Dr. Di Bisceglie received his medical degree from the University of Witwatersrand, Johannesburg, South Africa in 1977 and completed his training in Internal Medicine at Baragwanath Hospital, …See details»
Arbutus Provides 2025 Corporate and Financial Update
Jan 13, 2025 AB-101-001 is a Phase 1a/1b double-blind, randomized, placebo-controlled clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK), and …See details»
Home | Arbutus Biopharma
About Arbutus Biopharma. Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) clinical-stage biopharmaceutical company primarily focused on discovering, developing and …See details»
Genevant Sciences and Arbutus Biopharma Initiate International …
Mar 3, 2025 The company is currently developing imdusiran (AB-729) for the treatment of chronic hepatitis B (cHBV). Through its ownership stake in and license agreement with …See details»
Arbutus Provides 2025 Corporate and Financial Update
Jan 13, 2025 The World Health Organization estimates that over 250 million people worldwide suffer from chronic HBV infection, while other estimates indicate that approximately 2 million …See details»
Establishing Canada’s first large-scale bioinnovation centre
Mar 20, 2025 Today, the Honourable Darren Fisher, Member of Parliament for Dartmouth – Cole Harbour, announced a $5 million, non-repayable contribution to Neptune BioInnovation Inc. to …See details»
Arbutus Provides 2025 Corporate and Financial Update
Jan 13, 2025 The World Health Organization estimates that over 250 million people worldwide suffer from chronic HBV infection, while other estimates indicate that approximately 2 million …See details»